185 related articles for article (PubMed ID: 35776160)
1. The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer.
Nose Y; Saito T; Yamamoto K; Yamashita K; Tanaka K; Yamamoto K; Makino T; Takahashi T; Kawashima A; Haruna M; Hirata M; Ueyama A; Iwahori K; Satoh T; Kurokawa Y; Eguchi H; Doki Y; Wada H
Cancer Immunol Immunother; 2023 Jan; 72(1):169-181. PubMed ID: 35776160
[TBL] [Abstract][Full Text] [Related]
2. Significance of CD103
Natsuki S; Tanaka H; Nishiyama M; Deguchi S; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Maeda K
BMC Cancer; 2023 Oct; 23(1):1011. PubMed ID: 37864146
[TBL] [Abstract][Full Text] [Related]
3. OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody.
Ohmura H; Yamaguchi K; Hanamura F; Ito M; Makiyama A; Uchino K; Shimokawa H; Tamura S; Esaki T; Mitsugi K; Shibata Y; Oda H; Tsuchihashi K; Ariyama H; Kusaba H; Oda Y; Akashi K; Baba E
Br J Cancer; 2020 May; 122(10):1507-1517. PubMed ID: 32203221
[TBL] [Abstract][Full Text] [Related]
4. Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients.
Capone M; Fratangelo F; Giannarelli D; Sorrentino C; Turiello R; Zanotta S; Galati D; Madonna G; Tuffanelli M; Scarpato L; Grimaldi AM; Esposito A; Azzaro R; Pinto A; Cavalcanti E; Pinto A; Morello S; Ascierto PA
J Transl Med; 2020 Mar; 18(1):121. PubMed ID: 32160899
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
[TBL] [Abstract][Full Text] [Related]
6. CD45RA
Kunert A; Basak EA; Hurkmans DP; Balcioglu HE; Klaver Y; van Brakel M; Oostvogels AAM; Lamers CHJ; Bins S; Koolen SLW; van der Veldt AAM; Sleijfer S; Mathijssen RHJ; Aerts JGJV; Debets R
J Immunother Cancer; 2019 Jun; 7(1):149. PubMed ID: 31176366
[TBL] [Abstract][Full Text] [Related]
7. Immune profiling identifies CD8
Chen Z; Guo ML; Li YY; Yan K; Li L; Shen F; Guan H; Liu QZ; Xu B; Lian ZX
Front Immunol; 2022; 13():894919. PubMed ID: 36420264
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103
Li R; Liu H; Cao Y; Wang J; Chen Y; Qi Y; Lv K; Liu X; Yu K; Lin C; Zhang H; He H; Li H; Chen L; Shen Z; Qin J; Zhang W; Sun Y; Xu J
Br J Cancer; 2020 May; 122(10):1525-1534. PubMed ID: 32205862
[TBL] [Abstract][Full Text] [Related]
9. Distribution, phenotype, functional and clinical relevance of CD8
Shen Y; Li XL; Li YX; Shan ZG; Zhao YL; Cheng P; Zhao Z; Zhang JY; Chen W; Zhuang Y; Ma DY; Zou QM; Qiu Y; Peng LS
Cancer Immunol Immunother; 2022 Jul; 71(7):1645-1654. PubMed ID: 34767045
[TBL] [Abstract][Full Text] [Related]
10. The First-week Proliferative Response of Peripheral Blood PD-1
Kim KH; Cho J; Ku BM; Koh J; Sun JM; Lee SH; Ahn JS; Cheon J; Min YJ; Park SH; Park K; Ahn MJ; Shin EC
Clin Cancer Res; 2019 Apr; 25(7):2144-2154. PubMed ID: 30647082
[TBL] [Abstract][Full Text] [Related]
11. Immune profile analysis of peripheral blood and tumors of lung cancer patients treated with immune checkpoint inhibitors.
Ichiki Y; Fukuyama T; Ueno M; Kanasaki Y; Goto H; Takahashi M; Mikami S; Kobayashi N; Nakanishi K; Hayashi S; Ishida T
Transl Lung Cancer Res; 2022 Nov; 11(11):2192-2207. PubMed ID: 36519023
[TBL] [Abstract][Full Text] [Related]
12. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer.
Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
[TBL] [Abstract][Full Text] [Related]
14. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
[TBL] [Abstract][Full Text] [Related]
15. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
[TBL] [Abstract][Full Text] [Related]
16. Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients.
Shimoda Y; Yoshida T; Shirasawa M; Mizuno T; Jo H; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y; Motoi N
Anticancer Res; 2021 Nov; 41(11):5739-5747. PubMed ID: 34732447
[TBL] [Abstract][Full Text] [Related]
17. Peripheral T cell cytotoxicity predicts the efficacy of anti-PD-1 therapy for advanced non-small cell lung cancer patients.
Iwahori K; Uenami T; Yano Y; Ueda T; Tone M; Naito Y; Suga Y; Fukushima K; Shiroyama T; Miyake K; Koyama S; Hirata H; Nagatomo I; Kida H; Mori M; Takeda Y; Kumanogoh A; Wada H
Sci Rep; 2022 Oct; 12(1):17461. PubMed ID: 36261600
[TBL] [Abstract][Full Text] [Related]
18. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
Narducci MG; Tosi A; Frezzolini A; Scala E; Passarelli F; Bonmassar L; Monopoli A; Accetturi MP; Cantonetti M; Antonini Cappellini GC; De Galitiis F; Rosato A; Picozza M; Russo G; D'Atri S
Front Immunol; 2020; 11():579894. PubMed ID: 33072126
[TBL] [Abstract][Full Text] [Related]
19. Implication of CD69
Kim HD; Jeong S; Park S; Lee YJ; Ju YS; Kim D; Song GW; Lee JH; Kim SY; Shin J; Shin EC; Hwang S; Yoo C; Park SH
Liver Int; 2021 Apr; 41(4):764-776. PubMed ID: 33548061
[TBL] [Abstract][Full Text] [Related]
20. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
